Compare REX AI Equity Premium Income ETF (AIPI) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
REX AI Equity Premium Income ETF vs Merck & Co., Inc. — how do they compare? REX AI Equity Premium Income ETF trades at $36.06, while Merck & Co., Inc. trades at $125.4 (market cap $318.26B). The key difference: Merck & Co., Inc. pays a 2.64% dividend while REX AI Equity Premium Income ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, REX AI Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| AIPI | MRK | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $44.93 | $129.52 |
52-Week Low | $32.45 | $77.60 |
Market Cap | — | $318.26B |
Enterprise Value | — | $361.68B |
Dividend Yield | — | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIPI trades at $37.10, up 1.87% with neutral technical signals. The ETF maintains a high weekly dividend distribution strategy, recently transitioning to weekly payouts. Technical analysis shows mixed signals with bullish moving averages but neutral oscillators, trading near key support at $37. Recent news highlights concerns about NAV erosion risk despite the attractive yield structure.
The outlook remains cautious due to structural limitations in the option-writing strategy that caps upside potential. While the ~34.8% yield appears attractive, sustainability depends heavily on AI market momentum. Investors face NAV erosion risk if technology sector performance falters, requiring careful monitoring of the fund's premium income strategy effectiveness.
Merck (MRK) trades at $126.78, showing stable recent performance with strong institutional interest. The company demonstrates solid fundamentals with 2025 revenue of $65.01B and net income of $18.25B, representing a 28.07% profit margin. Recent earnings have consistently beaten expectations, and the company is actively expanding through strategic acquisitions like Terns Pharmaceuticals. Technical indicators show a bullish trend with moving averages supporting upward momentum, though oscillators suggest some consolidation may be needed.
Merck presents a compelling investment case with strong profitability, consistent earnings beats, and strategic pipeline expansion through M&A. The stock offers 9.9% upside to the consensus price target of $139.33, supported by 67.6% analyst buy ratings. Key risks include patent expirations, competitive pressures in oncology, and integration challenges from recent acquisitions. The company's robust cash flow generation supports continued dividend payments and strategic investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About REX AI Equity Premium Income ETF
AIPI provides exposure to leading artificial intelligence firms while seeking to generate monthly income. It uses a covered call strategy to capture premiums from the volatility of AI-related stocks.
Read more on AIPI →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
